The Federal Trade Commission decides not to pursue investigations into health claims substantiation for Prestige Brands' Chloraseptic Defense Daily Health Strips and Insight Pharmaceuticals' Sucrets Defense lozenges in part because both products have been permanently discontinued, FTC states in June 1 letters to the companies. The Chloraseptic Defense strips claimed to boost the immune system and prevent flu and cold. Similarly, Sucrets Defense claimed to boost the immune system and fight colds as well as provide protection before entering crowded places. Other factors leading to FTC's decisions to not pursue the investigations include the short periods of time the products were marketed, the limited nature of the products' ad campaigns and relatively small resulting sales, FTC states...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The European Medicines Agency’s human medicines committee, the CHMP, has recommended 14 new medicines for pan-EU approval this month, including five orphan medicines.
The European Medicines Agency says that Eli Lilly's Alzheimer's disease drug should be approved for use in the EU, now that it has re-examined the negative opinion it previously adopted.
The European Medicines Agency recommended against pan-EU marketing authorization of Roche/Sarpeta’s gene therapy Elevidys for the treatment of Duchenne muscular dystrophy as the US reported another death in an Elevidys patient.
